NCT07141914

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 285,327 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.

Conditions

• Overweight
• Obesity
• Heart Failure (HF)
• Atherosclerotic Cardiovascular Disease (ASCVD)
• Primary Prevention

Interventions

Type	Name	Description
OTHER	No treatment given	No treatment given
OTHER	No treatment given	No treatment given

Timeline

• Start date: 2025-08-29
• Primary completion: 2025-12-19
• Completion: 2025-12-19
• First posted: 2025-08-26
• Last updated: 2026-01-23

Locations

1 site across 1 country: United States